PHYRAGO

Product NDC: 70709-156
11-digit product format: 707090156
Labeler code: 70709
Product ID: 70709-156_4701be7c-c558-40ba-9075-b3df5a84e84f
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: dasatinib
Dosage form: TABLET
Route: ORAL
Labeler: Cycle Pharmaceuticals Ltd
Application: NDA216099
Marketing category: NDA
Marketing start: 2025-09-22
Substance: DASATINIB
Active strength: 140 mg/1
Pharmacologic classes: Cytochrome P450 3A4 Inhibitors [MoA], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]
NDC exclude flag: No
Listing certified through: 2027-12-31
Current FDA listing: Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 6 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	RLD / RS	Approval date
N216099-001	PHYRAGO	DASATINIB	20MG	TABLET / ORAL	RLD	2023-12-05
N216099-002	PHYRAGO	DASATINIB	50MG	TABLET / ORAL	RLD	2023-12-05
N216099-003	PHYRAGO	DASATINIB	70MG	TABLET / ORAL	RLD	2023-12-05
N216099-004	PHYRAGO	DASATINIB	80MG	TABLET / ORAL	RLD	2023-12-05
N216099-005	PHYRAGO	DASATINIB	100MG	TABLET / ORAL	RLD, RS	2023-12-05
N216099-006	PHYRAGO	DASATINIB	140MG	TABLET / ORAL	RLD	2023-12-05

Orange Book patents#

Current patent rows page 1 of 2 · 120 matching rows.

Application-product, Patent, Expiration table
Application-product	Patent	Expiration	Use code	Coverage / status	Submission date
N216099-001	11202778	2041-01-22	U-3770		2023-12-22
N216099-001	11202778	2041-01-22	U-3771		2023-12-22
N216099-001	11202778	2041-01-22	U-3772		2023-12-22
N216099-001	11298356	2041-01-22		Drug product	2023-12-22
N216099-001	11324745	2041-01-22	U-3767		2023-12-22
N216099-001	11324745	2041-01-22	U-3768		2023-12-22
N216099-001	11324745	2041-01-22	U-3769		2023-12-22
N216099-001	12433891	2041-01-22	U-3767		2025-10-21
N216099-001	12433891	2041-01-22	U-3768		2025-10-21
N216099-001	12433891	2041-01-22	U-3769		2025-10-21
N216099-001	12433891	2041-01-22	U-3770		2025-10-21
N216099-001	12433891	2041-01-22	U-3771		2025-10-21
N216099-001	12433891	2041-01-22	U-3772		2025-10-21
N216099-001	12465606	2041-01-22		Drug product	2025-11-14
N216099-001	12544376	2041-01-22	U-3767		2026-02-17
N216099-001	12544376	2041-01-22	U-3768		2026-02-17
N216099-001	12544376	2041-01-22	U-3769		2026-02-17
N216099-001	12544376	2041-01-22	U-3770		2026-02-17
N216099-001	12544376	2041-01-22	U-3771		2026-02-17
N216099-001	12544376	2041-01-22	U-3772		2026-02-17
N216099-002	11202778	2041-01-22	U-3770		2023-12-22
N216099-002	11202778	2041-01-22	U-3771		2023-12-22
N216099-002	11202778	2041-01-22	U-3772		2023-12-22
N216099-002	11298356	2041-01-22		Drug product	2023-12-22
N216099-002	11324745	2041-01-22	U-3767		2023-12-22
N216099-002	11324745	2041-01-22	U-3768		2023-12-22
N216099-002	11324745	2041-01-22	U-3769		2023-12-22
N216099-002	12433891	2041-01-22	U-3767		2025-10-21
N216099-002	12433891	2041-01-22	U-3768		2025-10-21
N216099-002	12433891	2041-01-22	U-3769		2025-10-21
N216099-002	12433891	2041-01-22	U-3770		2025-10-21
N216099-002	12433891	2041-01-22	U-3771		2025-10-21
N216099-002	12433891	2041-01-22	U-3772		2025-10-21
N216099-002	12465606	2041-01-22		Drug product	2025-11-14
N216099-002	12544376	2041-01-22	U-3767		2026-02-17
N216099-002	12544376	2041-01-22	U-3768		2026-02-17
N216099-002	12544376	2041-01-22	U-3769		2026-02-17
N216099-002	12544376	2041-01-22	U-3770		2026-02-17
N216099-002	12544376	2041-01-22	U-3771		2026-02-17
N216099-002	12544376	2041-01-22	U-3772		2026-02-17
N216099-003	11202778	2041-01-22	U-3770		2023-12-22
N216099-003	11202778	2041-01-22	U-3771		2023-12-22
N216099-003	11202778	2041-01-22	U-3772		2023-12-22
N216099-003	11298356	2041-01-22		Drug product	2023-12-22
N216099-003	11324745	2041-01-22	U-3767		2023-12-22
N216099-003	11324745	2041-01-22	U-3768		2023-12-22
N216099-003	11324745	2041-01-22	U-3769		2023-12-22
N216099-003	12433891	2041-01-22	U-3767		2025-10-21
N216099-003	12433891	2041-01-22	U-3768		2025-10-21
N216099-003	12433891	2041-01-22	U-3769		2025-10-21
N216099-003	12433891	2041-01-22	U-3770		2025-10-21
N216099-003	12433891	2041-01-22	U-3771		2025-10-21
N216099-003	12433891	2041-01-22	U-3772		2025-10-21
N216099-003	12465606	2041-01-22		Drug product	2025-11-14
N216099-003	12544376	2041-01-22	U-3767		2026-02-17
N216099-003	12544376	2041-01-22	U-3768		2026-02-17
N216099-003	12544376	2041-01-22	U-3769		2026-02-17
N216099-003	12544376	2041-01-22	U-3770		2026-02-17
N216099-003	12544376	2041-01-22	U-3771		2026-02-17
N216099-003	12544376	2041-01-22	U-3772		2026-02-17
N216099-004	11202778	2041-01-22	U-3770		2023-12-22
N216099-004	11202778	2041-01-22	U-3771		2023-12-22
N216099-004	11202778	2041-01-22	U-3772		2023-12-22
N216099-004	11298356	2041-01-22		Drug product	2023-12-22
N216099-004	11324745	2041-01-22	U-3767		2023-12-22
N216099-004	11324745	2041-01-22	U-3768		2023-12-22
N216099-004	11324745	2041-01-22	U-3769		2023-12-22
N216099-004	12433891	2041-01-22	U-3767		2025-10-21
N216099-004	12433891	2041-01-22	U-3768		2025-10-21
N216099-004	12433891	2041-01-22	U-3769		2025-10-21
N216099-004	12433891	2041-01-22	U-3770		2025-10-21
N216099-004	12433891	2041-01-22	U-3771		2025-10-21
N216099-004	12433891	2041-01-22	U-3772		2025-10-21
N216099-004	12465606	2041-01-22		Drug product	2025-11-14
N216099-004	12544376	2041-01-22	U-3767		2026-02-17
N216099-004	12544376	2041-01-22	U-3768		2026-02-17
N216099-004	12544376	2041-01-22	U-3769		2026-02-17
N216099-004	12544376	2041-01-22	U-3770		2026-02-17
N216099-004	12544376	2041-01-22	U-3771		2026-02-17
N216099-004	12544376	2041-01-22	U-3772		2026-02-17

Orange Book exclusivity#

Current exclusivity rows page 1 of 1 · 6 matching rows.

Application-product, Exclusivity code, Expiration table
Application-product	Exclusivity code	Expiration
N216099-001	M-307	2026-12-05
N216099-002	M-307	2026-12-05
N216099-003	M-307	2026-12-05
N216099-004	M-307	2026-12-05
N216099-005	M-307	2026-12-05
N216099-006	M-307	2026-12-05

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 120 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2026-10-15 13:18:30	2026-09	N216099-001	PHYRAGO	20MG	TABLET / ORAL	RLD	2023-12-05	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	PHYRAGO	50MG	TABLET / ORAL	RLD	2023-12-05	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-003	PHYRAGO	70MG	TABLET / ORAL	RLD	2023-12-05	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-004	PHYRAGO	80MG	TABLET / ORAL	RLD	2023-12-05	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-005	PHYRAGO	100MG	TABLET / ORAL	RLD, RS	2023-12-05	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-006	PHYRAGO	140MG	TABLET / ORAL	RLD	2023-12-05	`c2088c7a36db…`
2026-09-14 22:38:34	2026-08	N216099-001	PHYRAGO	20MG	TABLET / ORAL	RLD	2023-12-05	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N216099-002	PHYRAGO	50MG	TABLET / ORAL	RLD	2023-12-05	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N216099-003	PHYRAGO	70MG	TABLET / ORAL	RLD	2023-12-05	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N216099-004	PHYRAGO	80MG	TABLET / ORAL	RLD	2023-12-05	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N216099-005	PHYRAGO	100MG	TABLET / ORAL	RLD, RS	2023-12-05	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N216099-006	PHYRAGO	140MG	TABLET / ORAL	RLD	2023-12-05	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N216099-001	PHYRAGO	20MG	TABLET / ORAL	RLD	2023-12-05	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N216099-002	PHYRAGO	50MG	TABLET / ORAL	RLD	2023-12-05	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N216099-003	PHYRAGO	70MG	TABLET / ORAL	RLD	2023-12-05	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N216099-004	PHYRAGO	80MG	TABLET / ORAL	RLD	2023-12-05	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N216099-005	PHYRAGO	100MG	TABLET / ORAL	RLD, RS	2023-12-05	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N216099-006	PHYRAGO	140MG	TABLET / ORAL	RLD	2023-12-05	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N216099-001	PHYRAGO	20MG	TABLET / ORAL	RLD	2023-12-05	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N216099-002	PHYRAGO	50MG	TABLET / ORAL	RLD	2023-12-05	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N216099-003	PHYRAGO	70MG	TABLET / ORAL	RLD	2023-12-05	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N216099-004	PHYRAGO	80MG	TABLET / ORAL	RLD	2023-12-05	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N216099-005	PHYRAGO	100MG	TABLET / ORAL	RLD, RS	2023-12-05	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N216099-006	PHYRAGO	140MG	TABLET / ORAL	RLD	2023-12-05	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N216099-001	PHYRAGO	20MG	TABLET / ORAL	RLD	2023-12-05	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N216099-002	PHYRAGO	50MG	TABLET / ORAL	RLD	2023-12-05	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N216099-003	PHYRAGO	70MG	TABLET / ORAL	RLD	2023-12-05	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N216099-004	PHYRAGO	80MG	TABLET / ORAL	RLD	2023-12-05	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N216099-005	PHYRAGO	100MG	TABLET / ORAL	RLD, RS	2023-12-05	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N216099-006	PHYRAGO	140MG	TABLET / ORAL	RLD	2023-12-05	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N216099-001	PHYRAGO	20MG	TABLET / ORAL	RLD	2023-12-05	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N216099-002	PHYRAGO	50MG	TABLET / ORAL	RLD	2023-12-05	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N216099-003	PHYRAGO	70MG	TABLET / ORAL	RLD	2023-12-05	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N216099-004	PHYRAGO	80MG	TABLET / ORAL	RLD	2023-12-05	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N216099-005	PHYRAGO	100MG	TABLET / ORAL	RLD, RS	2023-12-05	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N216099-006	PHYRAGO	140MG	TABLET / ORAL	RLD	2023-12-05	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N216099-001	PHYRAGO	20MG	TABLET / ORAL	RLD	2023-12-05	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N216099-002	PHYRAGO	50MG	TABLET / ORAL	RLD	2023-12-05	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N216099-003	PHYRAGO	70MG	TABLET / ORAL	RLD	2023-12-05	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N216099-004	PHYRAGO	80MG	TABLET / ORAL	RLD	2023-12-05	`fd3edfee7708…`

Observed Orange Book patent history#

Patent history page 1 of 31 · 1,236 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Patent	Expiration	Use code	Coverage / status	Submission date	Source SHA-256
2026-10-15 13:18:30	2026-09	N216099-001	11202778	2041-01-22	U-3770		2023-12-22	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	11202778	2041-01-22	U-3771		2023-12-22	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	11202778	2041-01-22	U-3772		2023-12-22	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	11298356	2041-01-22		Drug product	2023-12-22	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	11324745	2041-01-22	U-3767		2023-12-22	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	11324745	2041-01-22	U-3768		2023-12-22	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	11324745	2041-01-22	U-3769		2023-12-22	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	12433891	2041-01-22	U-3769		2025-10-21	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	12433891	2041-01-22	U-3768		2025-10-21	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	12433891	2041-01-22	U-3767		2025-10-21	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	12433891	2041-01-22	U-3770		2025-10-21	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	12433891	2041-01-22	U-3771		2025-10-21	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	12433891	2041-01-22	U-3772		2025-10-21	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	12465606	2041-01-22		Drug product	2025-11-14	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	12544376	2041-01-22	U-3767		2026-02-17	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	12544376	2041-01-22	U-3768		2026-02-17	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	12544376	2041-01-22	U-3769		2026-02-17	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	12544376	2041-01-22	U-3770		2026-02-17	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	12544376	2041-01-22	U-3771		2026-02-17	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-001	12544376	2041-01-22	U-3772		2026-02-17	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	11202778	2041-01-22	U-3770		2023-12-22	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	11202778	2041-01-22	U-3771		2023-12-22	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	11202778	2041-01-22	U-3772		2023-12-22	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	11298356	2041-01-22		Drug product	2023-12-22	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	11324745	2041-01-22	U-3768		2023-12-22	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	11324745	2041-01-22	U-3769		2023-12-22	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	11324745	2041-01-22	U-3767		2023-12-22	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	12433891	2041-01-22	U-3768		2025-10-21	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	12433891	2041-01-22	U-3767		2025-10-21	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	12433891	2041-01-22	U-3769		2025-10-21	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	12433891	2041-01-22	U-3770		2025-10-21	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	12433891	2041-01-22	U-3771		2025-10-21	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	12433891	2041-01-22	U-3772		2025-10-21	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	12465606	2041-01-22		Drug product	2025-11-14	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	12544376	2041-01-22	U-3767		2026-02-17	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	12544376	2041-01-22	U-3768		2026-02-17	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	12544376	2041-01-22	U-3769		2026-02-17	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	12544376	2041-01-22	U-3770		2026-02-17	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	12544376	2041-01-22	U-3771		2026-02-17	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	12544376	2041-01-22	U-3772		2026-02-17	`c2088c7a36db…`

Observed Orange Book exclusivity history#

Exclusivity history page 1 of 3 · 84 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Exclusivity code	Expiration	Source SHA-256
2026-10-15 13:18:30	2026-09	N216099-001	M-307	2026-12-05	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-002	M-307	2026-12-05	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-003	M-307	2026-12-05	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-004	M-307	2026-12-05	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-005	M-307	2026-12-05	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N216099-006	M-307	2026-12-05	`c2088c7a36db…`
2026-09-14 22:38:34	2026-08	N216099-001	M-307	2026-12-05	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N216099-002	M-307	2026-12-05	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N216099-003	M-307	2026-12-05	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N216099-004	M-307	2026-12-05	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N216099-005	M-307	2026-12-05	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N216099-006	M-307	2026-12-05	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N216099-001	M-307	2026-12-05	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N216099-002	M-307	2026-12-05	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N216099-003	M-307	2026-12-05	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N216099-004	M-307	2026-12-05	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N216099-005	M-307	2026-12-05	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N216099-006	M-307	2026-12-05	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N216099-001	M-307	2026-12-05	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N216099-002	M-307	2026-12-05	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N216099-003	M-307	2026-12-05	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N216099-004	M-307	2026-12-05	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N216099-005	M-307	2026-12-05	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N216099-006	M-307	2026-12-05	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N216099-001	M-307	2026-12-05	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N216099-002	M-307	2026-12-05	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N216099-003	M-307	2026-12-05	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N216099-004	M-307	2026-12-05	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N216099-005	M-307	2026-12-05	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N216099-006	M-307	2026-12-05	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N216099-001	M-307	2026-12-05	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N216099-002	M-307	2026-12-05	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N216099-003	M-307	2026-12-05	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N216099-004	M-307	2026-12-05	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N216099-005	M-307	2026-12-05	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N216099-006	M-307	2026-12-05	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N216099-001	M-307	2026-12-05	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N216099-002	M-307	2026-12-05	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N216099-003	M-307	2026-12-05	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N216099-004	M-307	2026-12-05	`fd3edfee7708…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

Additional Listing Data#

Finished product: Yes
Brand name base: PHYRAGO
Listing expiration: 2027-12-31

Active Ingredients#

Ingredient, Strength table
Ingredient	Strength
DASATINIB	140 mg/1

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
b66e60ef-563e-ddb8-43b4-d625943af44b	Product name	3	20251209
820d87d5-5779-4353-ae7e-33904df346a1	Product name	1	20241218

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	Strength	SPL version
70709-156-14	PHYRAGO	30 in 1 BOTTLE	TABLET	30		3

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
70709-156-14	EA - Each	70709-156	fd34aaca-e7c5-4fdb-9cc2-cead2f80bf0a	1	2025-10-14

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
RBZ1571X5H	DASATINIB	863127-77-9	DASATINIB

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
799047	dasatinib 100 MG Oral Tablet	PSN	60976d1e-c415-417f-8168-4e07999a7281	3
1045402	dasatinib 140 MG Oral Tablet	PSN	60976d1e-c415-417f-8168-4e07999a7281	3
643105	dasatinib 20 MG Oral Tablet	PSN	60976d1e-c415-417f-8168-4e07999a7281	3
643107	dasatinib 50 MG Oral Tablet	PSN	60976d1e-c415-417f-8168-4e07999a7281	3
643109	dasatinib 70 MG Oral Tablet	PSN	60976d1e-c415-417f-8168-4e07999a7281	3
1045406	dasatinib 80 MG Oral Tablet	PSN	60976d1e-c415-417f-8168-4e07999a7281	3
2691837	PHYRAGO 100 MG Oral Tablet	PSN	60976d1e-c415-417f-8168-4e07999a7281	3
2691839	PHYRAGO 140 MG Oral Tablet	PSN	60976d1e-c415-417f-8168-4e07999a7281	3
2691841	PHYRAGO 20 MG Oral Tablet	PSN	60976d1e-c415-417f-8168-4e07999a7281	3
2691843	PHYRAGO 50 MG Oral Tablet	PSN	60976d1e-c415-417f-8168-4e07999a7281	3
2691845	PHYRAGO 70 MG Oral Tablet	PSN	60976d1e-c415-417f-8168-4e07999a7281	3
2691847	PHYRAGO 80 MG Oral Tablet	PSN	60976d1e-c415-417f-8168-4e07999a7281	3
2691837	dasatinib 100 MG Oral Tablet [Phyrago]	SBD	60976d1e-c415-417f-8168-4e07999a7281	3
2691839	dasatinib 140 MG Oral Tablet [Phyrago]	SBD	60976d1e-c415-417f-8168-4e07999a7281	3
2691841	dasatinib 20 MG Oral Tablet [Phyrago]	SBD	60976d1e-c415-417f-8168-4e07999a7281	3
2691843	dasatinib 50 MG Oral Tablet [Phyrago]	SBD	60976d1e-c415-417f-8168-4e07999a7281	3
2691845	dasatinib 70 MG Oral Tablet [Phyrago]	SBD	60976d1e-c415-417f-8168-4e07999a7281	3
2691847	dasatinib 80 MG Oral Tablet [Phyrago]	SBD	60976d1e-c415-417f-8168-4e07999a7281	3
799047	dasatinib 100 MG Oral Tablet	SCD	60976d1e-c415-417f-8168-4e07999a7281	3
1045402	dasatinib 140 MG Oral Tablet	SCD	60976d1e-c415-417f-8168-4e07999a7281	3
643105	dasatinib 20 MG Oral Tablet	SCD	60976d1e-c415-417f-8168-4e07999a7281	3
643107	dasatinib 50 MG Oral Tablet	SCD	60976d1e-c415-417f-8168-4e07999a7281	3
643109	dasatinib 70 MG Oral Tablet	SCD	60976d1e-c415-417f-8168-4e07999a7281	3
1045406	dasatinib 80 MG Oral Tablet	SCD	60976d1e-c415-417f-8168-4e07999a7281	3
2691837	Phyrago 100 MG Oral Tablet	SY	60976d1e-c415-417f-8168-4e07999a7281	3
2691839	Phyrago 140 MG Oral Tablet	SY	60976d1e-c415-417f-8168-4e07999a7281	3
2691841	Phyrago 20 MG Oral Tablet	SY	60976d1e-c415-417f-8168-4e07999a7281	3
2691843	Phyrago 50 MG Oral Tablet	SY	60976d1e-c415-417f-8168-4e07999a7281	3
2691845	Phyrago 70 MG Oral Tablet	SY	60976d1e-c415-417f-8168-4e07999a7281	3
2691847	Phyrago 80 MG Oral Tablet	SY	60976d1e-c415-417f-8168-4e07999a7281	3

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Units	Marketing start	Sample	Exclude flag	Status
70709-156-14	70709015614	30 TABLET in 1 BOTTLE (70709-156-14)	30 tablet	2025-09-22	No	No	Current

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
PHYRAGO	Cycle Pharmaceuticals Ltd \| Bora Pharmaceutical Services Inc \| MSN Laboratories Private Limited	2026-10-19	HUMAN PRESCRIPTION DRUG LABEL	4